Traditional Chinese medicine composition for treating advanced non-small cell lung cancer and preparing method and application thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating the advanced non-small cell lung cancer and a preparing method and application thereof, and relates to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition comprises, by weight, 5-15 parts of ginseng, 20-40 parts of radix astragali, 5-15 parts of radix adenophorae, 5-15 parts of radix ophiopogonis, 5-15 parts of dried tangerine peel, 5-15 parts of pinellia ternata, 5-15 parts of bulbus fritillariae cirrhosae, 5-15 parts of radix angelicae sinensis, 3-7 partsof pseudo-ginseng, 10-20 parts of barbed skullcap herb, 20-40 parts of oldenlandia diffusa, 10-20 parts of poria cocos, 5-15 parts of rhizoma atractylodis macrocephalae, 5-15 parts of thunberg fritillary bulb, 20-40 parts of semen coicis, 5-15 parts of aster, 5-15 parts of radix stemonae, 5-15 parts of platycodon grandiflorum and 5-15 parts of honey-fried licorice root. With the traditional Chinese medicine theory as the guidance, according to the treatment rule of tonifying qi and yin, promoting blood circulation to remove phlegm, and removing toxic materials and stasis, the traditional Chinese medicine composition is mild in medicine property, strict in compatibility, clear in pharmacodynamics matter and remarkable in clinical treatment effect when used for treating the advanced non-small cell lung cancer.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine preparations, and in particular relates to a traditional Chinese medicine composition for treating advanced non-small cell lung cancer, a preparation method and application thereof. Background technique [0002] Lung cancer, or primary bronchogenic carcinoma, is a malignant tumor originating from respiratory epithelial cells (bronchi, bronchioles and alveoli), and is the malignant tumor with the highest morbidity and mortality. In 2012, there were 1.825 million new cases of lung cancer in the world, accounting for 13.0% of all cancer cases, and 1.590 million lung cancer deaths, accounting for 19.4% of all cancer deaths. Lung cancer was the most common cancer in China in 2015 and the leading cause of cancer-related deaths in China. According to histological lesions, it can be divided into small cell carcinoma (small celllung cancer, SCLC) and non-small cell carcinoma (non-smal...

AI Technical Summary

Problems solved by technology

However, early diagnosis and treatment of lung cancer are relatively difficult, and most patients with non-small cell lung cancer are already in the middle and advanced stages when they are diagnosed. Platinum-based first-line chemotherapy is still the main treatment for patients with unresectable non-small cell lung cancer. However, its toxic side effects are severe. , while killing cancer cells, it is easy to kill normal cells in the body. Immunosuppression is one of the important side effects of lung cancer chemotherapy, and its 5-year survival rate is only 18%.

Modern medical treatment measures for advanced non-small cell lung cancer are difficult to achieve satisfactory curative effect, and there are disadvantages such as poor curative effect, poor prognosis, and large side effects

Images